Toshiba's Hybrid Multi-function Peripheral Wins Better Buys Editor's Choice Award
Toshiba Tec Corporation (TOKYO:6588)'s e-STUDIO4508LP, the hybrid Multi-function peripheral (MFP) capable of producing erasable as well as standard monochrome prints, earned Better Buys Q3 2017 Editor's Choice Award. The industry's first-of-its-kind product received the coveted honor by outperforming a wide array of other monochrome copiers in side-by-side comparisons.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912005028/en/
Toshiba Tec Corporation's e-STUDIO4508LP, the hybrid Multi-function peripheral (MFP) capable of producing erasable as well as standard monochrome prints, earned Better Buys Q3 2017 Editor's Choice Award. The industry's first-of-its-kind product received the coveted honor by outperforming a wide array of other monochrome copiers in side-by-side comparisons. (Graphic: Business Wire)
Better Buys editors were especially impressed by the e-STUDIO4508LP's eco and cost-savings elements as well as the product's erasable toner. Featuring Toshiba's proprietary erasable toner, the e-STUDIO4508LP enables paper reuse by erasing all printed content on the page.
“The Toshiba e-STUDIO4508LP utilizes the same strong features as Toshiba’s other copiers," said Better Buys editor Melissa Pardo-Bunte. "However, it has innovative hybrid printing technology that will reduce expenses while limiting organizations' carbon footprints.”
Hybrid MFP allows users to print both regular black prints and erasable blue prints, and also erase the prints within one device. To simplify use, the product's rules-based printing feature enables users to select toner setting defaults based on the application. As a result, temporary items, such as emails, may be designated to print in erasable toner to conserve paper while more permanent documents such as those printed from Microsoft Word may be assigned to print in standard monochrome toner.
“We are pleased that the e-STUDIO4508LP’s unique feature was highly evaluated and won the award. It is the signature model of Toshiba Tec’s environmental strategy, and its hybrid printing technology will help our customers function more ecologically while still operating in an efficient and economical manner,” says Sachio Koyama, General Manager of Products, Marketing & Service Division, Printing Solutions Business Group, Toshiba Tec.
In addition to winning Better Buys Q3 2017 Editor's Choice Award, Toshiba has earned Better Buys' Innovative Product of the Year Award four out of the last five years.
About Better Buys
After more than 20 years as a trusted authority on office equipment, Better Buys is now a rebranded site that offers resources to help companies in the market for Business Intelligence solutions, HR Software, CMMS Systems, as well as printers, copiers, and scanners. Leveraging an experienced team of in-house editors, Better Buys offers a range of content and resources designed to help organizations make smarter purchasing decisions, including expert reviews, authoritative whitepapers & reports, insightful market research, comprehensive buyer’s guides, and more. For more information, visit www.betterbuys.com.
About Toshiba Tec
Toshiba Tec Corporation is a Toshiba’s group company, a leading provider of technology solutions, operating across multiple industries – ranging from retail, education and business services to hospitality and manufacturing. With headquarters in Japan and over 80 subsidiaries worldwide, Toshiba Tec Corporation helps organizations transform the way they create, record, share, manage and display information.
Unless otherwise specified and/or credited all images, artwork, text and graphics, logos and logotypes are the copyright and/or trademark of the respective owners. All rights reserved.
Toshiba Tec Corporation
Toshihiko “Tommy” Minato, +81-(0)50-3681-5528
Products, Marketing & Service Division
Printing Solutions Business Group
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 08:43 | Pressemelding
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova
Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 08:29 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em
Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 08:00 | Pressemelding
Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio
Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 08:00 | Pressemelding
(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p
Record Attendance at Japan Content Showcase 2017!20.11.2017 03:00 | Pressemelding
Japan Content Showcase 2017 was held October 23-26 at Ikebukuro Sunshine City and the Shibuya Excel Hotel Tokyu. A record 19,549 people participated in sales meetings, excluding the TIMM Showcase Live. Other new records this year were 371 exhibiting groups from 27 countries and regions and 1,549 buyers from 48 countries and regions. There was a significant increase in overseas buyers this year, the 1022 foreign registrations representing an increase of more than 10% over last year. The number of non-Japanese Asian buyers increased by 6%, North Americans by 13%, South Americans by 44%, and Europeans by 49%. The number of Middle Eastern buyers doubled, and there were more than five times the number of Russian buyers as last year. French buyers were up 70%, Italians 60%, British 75%, and Germans 50%. Business matching was a new service offered by the organizers this year. Meeti
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom